TG Therapeutics: Funding, Investors & Team (Oct 2026)
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".
TG Therapeutics has raised $320M across 2 funding rounds on record, the most recent an undisclosed round of $250M announced in Aug 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
TG Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2024.
TG Therapeutics Funding Rounds
TG Therapeutics raised $70.0M in a Post-IPO Debt announced in Jan 2022.
2.6 years later, an undisclosed round of $250M was announced in Aug 2024.
TG Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
TG Therapeutics Funding Compared to Other Biotechnology Startups
TG Therapeutics' latest round of $250M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like TG Therapeutics in Biotechnology and New York
Companies Similar to TG Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
TG Therapeutics Funding FAQs
What does TG Therapeutics do?
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".
How much funding has TG Therapeutics raised?
TG Therapeutics has raised $320M across 2 rounds on record. The most recent is an undisclosed round of $250M announced in Aug 2024.
When did TG Therapeutics last raise funding?
TG Therapeutics' most recent funding round on record is an undisclosed round of $250M, announced in Aug 2024.
Who founded TG Therapeutics?
FundedIQ lists Michael S. Weiss (Founder) at TG Therapeutics.
Who is the CEO of TG Therapeutics?
Michael Weiss is listed as CEO at TG Therapeutics.
Where is TG Therapeutics headquartered?
TG Therapeutics is based in New York, United States.
How many employees does TG Therapeutics have?
TG Therapeutics is in the 251-500 employee band.
How does TG Therapeutics' funding compare to other Biotechnology startups?
TG Therapeutics' latest round of $250M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's TG Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TG Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.